Regen BioPharma, Inc. provides update on NR2F6 small molecule optimization program for treating cancer and arthritis.
Regen BioPharma Inc. has provided an update on the status of its medicinal chemistry program being conducted by ChemDiv Inc. for the optimization of its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02.
The compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen’s patented screening methodology and unique chemical libraries.
ChemDiv Inc., a fully integrated target-to-clinic contract research organization, which is conducting the compound optimization studies for Regen BioPharma, has reported that they have synthesized more than 30 analogues of the initial small molecules and will begin screening them for activity in the coming weeks. Additionally, purified protein that will be used in these studies has been manufactured and received by the company.
Now that this crucial first phase has been completed, the company can move forward with ChemDiv on the actual optimization process, which involves introducing the synthesized compound analogues to the special NR2F6 protein molecule and cellular systems.
The NR2F6 nuclear receptor has been identified as a potentially significant immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6, in an effort to unleash the cancer-killing potential of a patient’s own immune system, as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as rheumatoid arthritis and other autoimmune diseases.
“The optimization process of small molecule development is iterative. It requires a series of compounds to be synthesized and their activity to be understood. By doing this repeatedly and learning about the relationship between structure and activity, optimized compounds are generated,” says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. “We are on track and on schedule. The next two months will be very important as we define the key portions of the structures that relate to activity in the protein molecule.”
“This is an extremely exciting time for Regen as we are moving the company dynamically forward,” stated David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. “The ChemDiv studies are the gateway to potentially strong relationships with one or more large pharmaceutical companies that have already express(ed) interest in our NR2F6 small molecule therapeutic models for treating cancer and arthritis immunologically.”
(Source: PR Newswire)
Filed Under: Drug Discovery